Winpocetyna nie tylko w zaburzeniach krążenia mózgowego Przedruk z: Biblioteka Medycyny Faktów 1/2013
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2014
Słowa kluczowe:
winpocetyna, zaburzenia krążenia mózgowego, neuroprotekcja, wielokierunkowość działania
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule przedstawiono wielokierunkowy mechanizm działania winpocetyny. Szczególną uwagę poświęcono zastosowaniu tej substancji leczniczej w wielu schorzeniach neurologicznych: zaburzeniach krążenia mózgowego, zaburzeniach poznawczych, otępieniu naczyniopochodnym i udarach mózgowych. Zwrócono uwagę na zastosowanie w otolaryngologii i okulistyce. Zaznaczono również znaczny profil bezpieczeństwa leku i niewielkie działania uboczne.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Porębska, B. (2014). Winpocetyna nie tylko w zaburzeniach krążenia mózgowego . Medycyna Faktów , 7(1(22), 23-26. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2377
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Zaremba M., Postuła M.: Wielokierunkowe działanie winpocetyny i korzyści z tym związane w świetle badań eksperymentalnych i klinicznych. Medycyna Faktów 2013; 6(2).
2. Bałkowiec-Iskra E., Joniec I.: Winpocetyna nowe wskazania do stosowania. Przew. Lek. 2005; 2: 32-39.
3. Miyata N., Yamaura H., Tanaka M. et al.: Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci. 1993; 52: 181-186.
4. Sitges M., Galván E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosome. Neurochem. Int. 2005; 46: 533-540.
5. Stolc S.: Indole derivatives as neuroprotectants. Life Sci. 1999; 65: 1943-1950.
6. Matsukawa M., Ogawa M., Nakadate K. et al.: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci. Lett. 1997; 230: 13-16.
7. Shibuya T., Sato K.: Effects of vinpocetine on experimental brain ischemia, histological study of brain monomines. Igaku No Ayumi 1986; 139: 217-219.
8. McDaniel M.A., Maier S.F., Einstein G.O.: Brain-specific nutrients: a memory cure? Nutrition 2003; 19: 957-975.
9. Feher G., Koltai K., Kesmarky G. et al.: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine 2009; 16: 111-117.
10. Szapáry L., Horváth B., Alexy T. et al.: [Effect of vinpocetine on the hemorheologic parameters in patients with chronic cerebrovascular disease]. Orv. Hetil. 2003; 144: 973-978.
11. Tohgi H., Sasaki K., Chiba K., Nozaki Y.: Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimittelforschung 1990; 40: 640-643.
12. Valikovics A.: [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60: 301-310.
13. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evasenile evaluation of the safety and efficacy of vinpocetine in the treatment of patient with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-30.
14. Yamaguchi T., Nagano H., Yamaguchi M.: The effects of kallidinogenase on choroidal blood flow in a hypertensive rabbit model. Curr. Eye Res. 1999; 18(6): 417-22.
15. Nekrassov V., Sitges M.: Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo. Brain Res. 2000; 868: 222-9.
16. Truss M.C., Stief C., Uckert S. et al.: Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to beside. World J. Urol. 2001; 19: 344-50.
17. Nosalova V., Machova J., Babulova A.: Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung 1993; 43: 981-985.
18. Hadjiev D.: Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz. 2003; 56(5–6): 166-72.
19. Gaal L., Monar P.: Effect of vinopocetine on noradrenergic neurons in rat locus coeruleus. Eur. J. Phamacol. 1990; 187: 537-539.
2. Bałkowiec-Iskra E., Joniec I.: Winpocetyna nowe wskazania do stosowania. Przew. Lek. 2005; 2: 32-39.
3. Miyata N., Yamaura H., Tanaka M. et al.: Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci. 1993; 52: 181-186.
4. Sitges M., Galván E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosome. Neurochem. Int. 2005; 46: 533-540.
5. Stolc S.: Indole derivatives as neuroprotectants. Life Sci. 1999; 65: 1943-1950.
6. Matsukawa M., Ogawa M., Nakadate K. et al.: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci. Lett. 1997; 230: 13-16.
7. Shibuya T., Sato K.: Effects of vinpocetine on experimental brain ischemia, histological study of brain monomines. Igaku No Ayumi 1986; 139: 217-219.
8. McDaniel M.A., Maier S.F., Einstein G.O.: Brain-specific nutrients: a memory cure? Nutrition 2003; 19: 957-975.
9. Feher G., Koltai K., Kesmarky G. et al.: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine 2009; 16: 111-117.
10. Szapáry L., Horváth B., Alexy T. et al.: [Effect of vinpocetine on the hemorheologic parameters in patients with chronic cerebrovascular disease]. Orv. Hetil. 2003; 144: 973-978.
11. Tohgi H., Sasaki K., Chiba K., Nozaki Y.: Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimittelforschung 1990; 40: 640-643.
12. Valikovics A.: [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60: 301-310.
13. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evasenile evaluation of the safety and efficacy of vinpocetine in the treatment of patient with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-30.
14. Yamaguchi T., Nagano H., Yamaguchi M.: The effects of kallidinogenase on choroidal blood flow in a hypertensive rabbit model. Curr. Eye Res. 1999; 18(6): 417-22.
15. Nekrassov V., Sitges M.: Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo. Brain Res. 2000; 868: 222-9.
16. Truss M.C., Stief C., Uckert S. et al.: Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to beside. World J. Urol. 2001; 19: 344-50.
17. Nosalova V., Machova J., Babulova A.: Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung 1993; 43: 981-985.
18. Hadjiev D.: Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz. 2003; 56(5–6): 166-72.
19. Gaal L., Monar P.: Effect of vinopocetine on noradrenergic neurons in rat locus coeruleus. Eur. J. Phamacol. 1990; 187: 537-539.